ProstaScint
ProstaScint Uses, Dosage, Side Effects, Food Interaction and all others data.
Capromab is a Murine IgG1 monoclonal 7E11-C5.3 antibody that recognizes prostate specific membrane antigen (PSMA – also known as glutamate carboxypeptidase 2) from prostate cancer cells and normal prostate tissue. When linked to pendetide, capromab is used as a chelating agent for the radionuclide Indium In-111 during imaging to evaluate the extent of prostate cancer.
Binds to the prostate-specific membrane antigen, which is a cell surface protein generally overexpressed in prostate tissues and prostate cancers. The radioactive Indium 111, which is covalently attached to the antibody, allows radiodiagnostic detection of PSMA expressing cells and tumors.
| Trade Name | ProstaScint |
| Generic | Capromab pendetide |
| Capromab pendetide Other Names | (111In)-Capromab pendetide, Capromab pendetide, Indium (111In) capromab pendetide, Indium 111 Capromab Pendetide, Indium In 111 capromab pendetide |
| Type | Injection |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | United States, |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
ProstaScint is a monoclonal anti-prostate specific membrane antigen antibody used in imaging kits to target radioactive agents to malignant prostate tissue.
For diagnosis of prostate cancer and detection of intra-pelvic metastases.
ProstaScint is also used to associated treatment for these conditions: Prostate Cancer
How ProstaScint works
Binds selectively to cell-surface prostate-specific membrane antigen (PSMA) expressed on prostate tissues and tumors.
Volume of Distribution
- 4 ± 2.1 L
Clearance
- 42 +/- 22 mL/hr
Elimination Route
Approximately 10% of the administered radioisotope dose is excreted in the urine during the 72 hours following intravenous infusion.
Innovators Monograph
You find simplified version here ProstaScint
